Methode Electronics (NYSE: MEI) and Transcat (NASDAQ:TRNS) are both small-cap industrials companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.
Risk & Volatility
Methode Electronics has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Transcat has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500.
This table compares Methode Electronics and Transcat’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Methode Electronics||$816.50 million||1.87||$92.90 million||$2.68||15.49|
|Transcat||$143.90 million||0.75||$4.52 million||$0.68||22.09|
Methode Electronics has higher revenue and earnings than Transcat. Methode Electronics is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
92.7% of Methode Electronics shares are owned by institutional investors. Comparatively, 55.2% of Transcat shares are owned by institutional investors. 4.4% of Methode Electronics shares are owned by insiders. Comparatively, 8.8% of Transcat shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Methode Electronics pays an annual dividend of $0.44 per share and has a dividend yield of 1.1%. Transcat does not pay a dividend. Methode Electronics pays out 16.4% of its earnings in the form of a dividend.
This is a breakdown of recent ratings and price targets for Methode Electronics and Transcat, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Methode Electronics presently has a consensus price target of $49.67, indicating a potential upside of 19.68%. Transcat has a consensus price target of $20.00, indicating a potential upside of 33.16%. Given Transcat’s higher probable upside, analysts plainly believe Transcat is more favorable than Methode Electronics.
This table compares Methode Electronics and Transcat’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Methode Electronics beats Transcat on 10 of the 14 factors compared between the two stocks.
About Methode Electronics
Methode Electronics, Inc. (Methode) is a manufacturer of component and subsystem devices. The Company designs, manufactures and markets devices employing electrical, radio remote control, electronic, wireless and sensing technologies. The Company operates through segments, including Automotive, Interface, Power Products and Other. The Automotive segment supplies electronic and electro-mechanical devices and related products to automobile original equipment manufacturers (OEMs). The Interface segment provides a range of copper and fiber-optic interface and interface solutions. The Power Products segment manufactures braided flexible cables, current-carrying laminated bus devices, custom power-product assemblies, such as PowerRail solution, high-current low voltage flexible power cabling systems and powder coated bus bars. The Other segment includes medical devices, inverters and battery systems, and insulated gate bipolar transistor solutions.
Transcat, Inc. is a provider of calibration and laboratory instrument services and a distributor of professional grade test, measurement and control instrumentation. The Company conducts its business through two segments: service (Service) and distribution (Distribution). Through the Service segment, the Company offers calibration, repair, inspection, analytical qualifications, preventative maintenance and other related services, a majority of which are processed through its asset management system, CalTrak (CalTrak). Through its Distribution segment, the Company markets, sells and rents national brand instruments to customers around the globe. The Company is focused on providing its services and products to the life science industries, which include pharmaceutical, biotechnology, medical device manufacturing and other Food and Drug Administration (FDA)-regulated businesses.
Receive News & Ratings for Methode Electronics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Methode Electronics and related companies with MarketBeat.com's FREE daily email newsletter.